Open database of authors and journals




Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

BioDrugs, 2021, 35, 337-350

Citation of paper, Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

Authors Citing This Paper

AuthorCiting PapersAuthor's PapersAuthor's CitationsAuthor's IF
Marc Peeters123916,4577.1
Paola A Marignani1341,7764.1

Journals Citing This Paper

JournalCiting PapersJournal's IFJournal's Star
Future Oncology13.6★★
Cancers16.6

Similar Articles

Quick Tips
This is an overview of where and by who this paper has been cited.
Help Us
Non-profit projects normally ask for donations. We don't. We will survive one way or another. If you wish to help us, please spread the word to let more people use this service.

It is delightful to see our efforts are useful to a broad range of researchers.
EXALY
Profiles
Fields
Search Engines
Tools